Robert Stein

Robert Stein has over 35 years of experience and accomplishments in the pharmaceutical and biotech industry. Over the course of his career, Dr. Stein has played a significant role in the discovery and development of eight marketed drugs, including Sustiva®, Fablyn®, Viviant®, PanRetin®, TargRetin®, Promacta®, and Eliquis®.

Currently, he is the EVP of R&D at MiMedx. Prior to this role, he was an advisor to Agenus, Inc’s global research, and development efforts. Dr. Stein has held a number of progressively responsible senior management positions including Head of Pharmacology for Merck & Co., CSO and SVP of Research for Ligand Pharmaceuticals, EVP of Research and Preclinical Development for Dupont Merck, President, and CSO for Incyte Pharmaceuticals, President of Roche Palo Alto, and CEO of KineMed. Dr. Stein spent the early part of his career at Merck, Sharp, and Dohme Research Laboratories.

He holds an MD and a Ph.D. in Physiology & Pharmacology from Duke University.